Among these, the effects of PD-L1, IDO and other inhibitory molecules on disablement of the therapeutic response, and localization and persistence of adoptively transferred therapeutic T cells with AML blasts will probably represent the major obstacles for the success of CARs in AML. This evidence concerns the gene IDO1 and acute myeloid leukemia.